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Introduction 
 
Although non-viral vectors are less efficient than viral vectors in transfecting airway 
epithelial cells, the former are currently the most relevant gene transfer agents for the 
treatment of chronic diseases such as cystic fibrosis (CF). In contrast to most viral 
vectors, non-viral gene transfer agents are less likely to induce immune responses, 
thereby allowing for repeated administration, a crucial aspect for the treatment of life-
long diseases. Importantly, proof-of-concept for repeat administration of cationic 
lipids to airway epithelium has been established in the clinic [1]. 
 
The cationic lipid GL67A (Genzyme Corporation) has been used in two CF gene 
therapy clinical trials [2,3] and has been shown  to produce partial correction 
(approximately 25% towards normal values) of the chloride transport defect [2]. We 
recently re-assessed the efficacy of GL67A compared two other non-viral vectors 
suitable for clinical use (manuscript in preparation) and, based on our studies, GL67A 
remains the most efficient non-viral vector for airway gene transfer. The level of 
correction of the CF defect that will produce clinical benefit is unknown. The UK 
Cystic Fibrosis Gene Therapy Consortium has, therefore, initiated a clinical trial 
programme to assess whether repeat administration of GL67A complexed to plasmid 
DNA carrying the cystic fibrosis transmembrane conductance regulator (CFTR) 
cDNA can improve clinically relevant endpoints in the CF lung.  
 
The target for CF gene therapy is the ciliated epithelium of the airways. Mucocilary 
clearance is a key defence mechanism in the conducting airways, removing inhaled 
bacteria and pollutants by sweeping them up to the pharynx where they are either 
coughed out or swallowed. However, this system may also reduce the efficacy of gene 
transfer by similarly removing gene transfer agents from the lungs. In this context, 
Sinn et al have interestingly shown that viscoelastic gel formulations, which inhibit 
mucocilary clearance increase viral gene transfer to the mouse airways [4]. Similarly 
Seiler et al have shown that thixotropic solutions enhance adenovirus mediated gene 
tranasfer [5].  No data are currently available for non-viral gene transfer.  
 
Here we, therefore, assessed the effect of two viscoelastic gels, methylcellulose (MC) 
and carboxymethylcellulose (CMC) on GL67A-mediated gene transfer to the airways 
of wild-type and CF-knockout mice. These polymers have been shown to be safe for 
use in man [6-8] and are present in numerous commercial pharmaceuticals including 
nasal sprays. Preliminary pre-clinical studies indicate that respiratory tissues treated 
with MC or CMC show no evidence of toxicity [9]. We assessed both the murine 
nasal epithelium, to allow assessment of correction of the ion transport defect in CF 
knockout mice, and the lung, given the downstream clinical application.  
Material and Methods 
 
Preparation of non-viral gene transfer agents 
Eukaryotic expression plasmids carrying no cDNA (pCIK-empty), the luciferase 
reporter gene cDNA (pCIKLux), the cystic  fibrosis transmembrance conductance 
regulator cDNA (pCIKCFTR) or a GFP-CFTR N-terminal fusion construct 
(pCIKGFP-CFTR) originally described by Moyer et al [10]  (cDNA was a gift from 
Dr B. Stanton) all under the control of the human cytomegalovirus immediate early 
promoter/enhancer (CMV) were used. Cationic lipid GL67A was supplied by 
Genzyme Corporation (Framingham, MA, USA) and complexed with DNA as 
previously described for nasal perfusion [11] and nebulisation [12].  Briefly, for nasal 
perfusion 80 g of plasmid DNA was complexed with GL67A in a 100 l total 
volume per mouse. For nebulisation 25 mg plasmid DNA were complexed with 
GL67A in a total volume of 10 ml. This volume was sufficient to simultaneously 
nebulise approximately 30 mice. Methylcellulose (MC, Methocel A4C; Dow 
Chemical Co., Midland, MI, USA) and Carboxymethlycellulose sodium (CMC, 
Aqualon 7MF; Hercules, Inc., Wilmington, DE, USA) were prepared as 2% (w/v) 
stock solutions in sterile water as previously described [4]. Lipid/DNA complexes 
were mixed with MC and CMC to final concentrations ranging from 0.5% to 1.5% in 
a total volume of 16 ml for nebulisation and 150 to 400 l for nasal perfusion (see 
Figures for details). For control groups appropriate amounts of sterile water instead of 
viscoelastic gels were added to the lipid/DNA complexes. 
 
Radiotracer efflux assay  
For the radiotracer efflux assay, HEK293T cells (1×10
5
 cells/well in pre-coated poly-
L-lysine 6-well plates (Becton–Dickinson, Oxford, UK)) were seeded 24 h before 
transfection.  Plasmids (1 g/well) were complexed to Lipofectamine™ 2000 (2.5 g, 
Invitrogen Ltd, Paisley, UK) according to manufacturer's recommendation. CFTR 
chloride channel activity was assayed by measuring the rate of 
125
iodide efflux 
essentially as previously described [13].  The 
125
iodide
 
efflux rates were normalised to 
the time of forskolin/IBMX addition (time t0). Curves were constructed by plotting 
rates of 
125
iodide efflux against time. To reflect the cumulative levels of 
125
iodide
 
efflux following agonist-stimulation, all comparisons were based on areas under the 
time-
125
iodide efflux curves, as calculated by the trapezium rule. Experiments were 
carried out in duplicate (n=6 wells/group/experiment).  
 
In vivo transfections  
Male and female C57Bl/6 mice (Charles River), or “gut-corrected” CF-knockout 
mice, [14] were used at approximately 6-12 weeks of age. All experiments were 
carried out with approval of appropriate local Ethics Committees and according to 
Home Office regulations.  
 
a.) Nasal perfusion:  
Mice were anaesthetised with Ketaset/Domitor (76 mg/kg and 1 mg/kg, respectively, 
National Veterinary Service, Stoke-on-Trent, UK). Catheters (<0.5 mm outer 
diameter) were inserted into the nostrils (approximately 2.5 mm) and using a syringe 
pump (Cole-Palmer, Illinois, USA) gene transfer agents (150 to 400 μl) were then 
perfused onto the nasal epithelium (7 μl/min) for approximately 22 to 60 min. At the 
end of the procedure mice, were injected i.p. with Antisedan (1 mg/kg, National 
Veterinary Services) to reverse the anaesthesia and placed in a recovery box at 30°C 
for 2 hours.  
b.) Nebulisation:  
Mice were placed into an exposure chamber and exposed to an aerosol generated by a 
PARI LC+ nebuliser (PARI GmbH, Starnberg, Germany) at a pressure of 22 psi for 1 
hr; 24 hours after transfection gene expression was quantified.  
 
Murine endpoint assays 
Preparation of tissue homogenate from mouse nose:  
Mice were culled by cervical dislocation and the snout, skin and nasal plate were 
removed. The septum was dissected and placed in 200 µl 1xRLB buffer (Promega, 
Southampton, UK). Nasal tissue was homogenised for 15 seconds and incubated at 
room temperature for 15 minutes, followed by three freeze-thaw cycles (-80
o
C for 30 
min, thawed at room temperature) and centrifugation (5 min at 16,000gav). The 
supernatant was frozen at -80
o
C for luciferase quantification.   
 
Preparation of tissue homogenate from mouse lung:  
The lungs were placed in 300 µl 1xRLB buffer (Promega, Southampton, UK) and 
homogenized using a Fast-Prep homogenizer (Thermo Fisher Scientific, Waltham, 
MA, USA) set to 4 m/sec for 45 seconds followed by 15 min incubation at room 
temperature. The supernatant was removed and transferred to a QiaShredder column 
(Qiagen, Crawley, Sussex) and centrifuged (1 min at 16,000gav) followed by an 
additional centrifugation (5 min at 16,000gav). The supernatant was frozen at -80
o
C 
for luciferase quantification.  
 
Luciferase assay:  
Luciferase activity was measured in the supernatant using a standard luciferase assay 
kit (Promega) and a TD-20e luminometer (Turner BioSystems, Sunnyvale, CA). Total 
protein per sample was determined using the BioRad protein assay kit (BioRad 
laboratories, Hercules, CA) and luciferase activity was expressed as arbitrary relative 
light units (RLU)/mg total protein.  
 
Real-time RT-PCR:  
An interdental brush (Curaprox CPS 07, Dent-o-Care Ltd, London, UK) was inserted 
2 mm into the right nasal cavity and then rolled along the septum to isolate respiratory 
epithelial cells. This harvesting method allowed collection of samples enriched to 
>80% for murine airway epithelial cells (E Holder, manuscript submitted). Cells were 
resuspended in RLT buffer (Qiagen Ltd, West Sussex, England) containing 1% -
mercaptoethanol and spun through a QIAshredder (Qiagen Ltd) to lyse the cells. Total 
RNA was extracted using the Qiagen RNeasy Mini kit (Qiagen Ltd). Contaminating 
DNA was removed using Ambion DNA-free
TM
 kit (Ambion Ltd, Huntingdon, UK) 
and RNA purified using the Qiagen RNA clean-up protocol. Absolute levels of 
mRNA were quantified by two-step, real-time quantitative TaqMan RT-PCR using 
the ABI PRISM 7700 Sequence Detection System and Sequence Detector v1.6.3 
software (Applied Biosystems, Warrington, Cheshire, UK), using plasmid or 
endogenous mRNA-specific primers and fluorogenic probes. Sequences of the 
forward (F), reverse (R), and probe (P) oligonucleotides used for each mRNA target 
are listed below, with the corresponding concentrations for TaqMan PCR. The R 
primer or a separate R2 primer were utilised in reverse transcriptase reactions. For 
pCIK-CFTR and pCIKGFP-CFTR, R2: 5’-GTC GTA TTA AGT ACT CTA GCC 
TT-3’, F: 5’-GCT TCT GAC ACA ACA GTC TCG AA-3’, R: 5’-GGA GTG GAC 
ACC TGC CCC A-3’, P: 5’-FAM-TGC CTC ACG ACC AAC TTC TGC AGC-3’; 
for murine Cftr, F: F: 5’-AGC CAG CTT TAT CTC CAA ACT CTT C-3’, R: 5’-
GCT GTC TGT ACC CTT TCC TCA AA-3’, P: 5’-VIC-TCA GCT GGA GCA CAG 
C-3’, respectively. Controls included no template control and no-reverse transcriptase 
(RT-) control where total RNA or MultiScribe reverse transcriptase and RNase 
inhibitor were omitted from the reverse transcriptase reaction, respectively. The 
number of copies of plasmid-derived mRNA was calculated from standard curves of 
in vitro transcribed RNA fragments that surrounded the amplified region [15].  
 
Immunohistochemistry:  
In our experience anti-CFTR antibodies are not particularly sensitive and we therefore 
decided to use a N-terminal GFP-CFTR fusion cDNA to monitor CFTR expression. 
CF knockout mice were transfected with pCIKGFP-CFTR or a control plasmid (pCIK 
empty) (n=10/group). In addition some mice were transfected with SeV-GFP-CFTR 
[16] at a dose of 10
8
 TU/mouse (n=6) as a positive control for the assay. Mice were 
anaesthetized 48 hr after transfection and perfused with phosphate-buffered saline 
(PBS, Sigma-Aldrich Steinheim, Germany) through the right ventricle to remove 
excess blood. The nasal septum lined with the epithelium was removed and fixed 
overnight in 4% paraformaldehyde (Sigma) in PBS at 4°C. Tissues were incubated in 
30% sucrose in PBS for approximately 6 hr and embedded into optimum cutting 
temperature compound (OCT, Sacura Finetek Europe, B.V) using standard 
histological procedures. Serial 6 µm sections (100 m apart) were cut (Bright Co, Ltd 
cryostat) approximately 2-3 mm from the tip of the nose, a region known to consist 
predominantly of respiratory epithelium, and placed on poly-L-lysine-coated slides 
(Thermo Shandon Ltd, Runcorn, Cheshire, UK). Slides were washed twice in PBS 
and incubated for 10 min at 100
o
C in EDTA buffer (1mM  EDTA in H20, pH 8, 
Sigma). Slides were cooled down for 20 mins and the EDTA buffer was replaced with 
0.1% Triton X100 (Sigma) in PBS (= wash buffer).  Slides were washed in wash 
buffer 4 times and incubated with polyclonal primary anti-GFP antibody (1:200 
dilution, Molecular Probes, Leiden, Holland) for 1 hr. Slides were washed and then 
incubated with secondary goat anti-rabbit antibody (1:200 dilution) conjugated to 
AlexaFluor 594 (Molecular Probes) for 1 hr. Slides were then washed 4 times in wash 
buffer, DAPI stained and mounted in Vectashield (Vector Laboratories, Burlingame, 
USA). Tissues were analysed using a Zeiss microscope (Zeiss Axioscop2 plus, Carl 
Zeiss, Gottingen, Germany, objective 63x/1.4, filter emission BP 515-565 ). All 
microscopy was performed blinded. 3 to 4 sections (300-400 cells/section) were 
analysed per mouse.  
 
Nasal potential difference:  
PD measurements in the mouse nose were performed as previously described [17], 
with minor modifications. In brief, mice were anaesthetised with Ketaset/Domitor, 
which minimised movement of mice during the procedure. The perfusion catheter was 
inserted 2.5 mm into the mouse nose. The baseline (BL) was measured and buffer 
containing amiloride was perfused for 5 min using a syringe pump. The amiloride 
response was read at the lowest point, when a plateau was reached. Low chloride 
solution was perfused for 8-10 min and the response was measured 7 min after 
starting perfusion. 
 
Statistical analysis 
Statistical analyses were performed by ANOVA and Kruskal-Wallis followed by 
post-hoc analysis appropriate for parametric and non-parametric data. The null 
hypothesis was rejected at p<0.05. 
Results 
 
Mouse nasal perfusion  
The formation of lipid/DNA complexes is based on electrostatic interactions between 
the cationic lipid and the anionic DNA, and is particularly sensitive to the addition of 
charged molecules. To minimise disturbance of complex formation, MC and CMC 
(0.1 to 1.5% final concentration) were added approximately 30 min after mixing the 
lipid and DNA. Using visual observation we did not observe any precipitation over a 
2 hr period, despite the fact that viscosity, based on visual observation, increased with 
increasing concentration of the compounds. 
 
We next determined if mice tolerated nasal perfusion of GL67A/DNA complexes (80 
g DNA in 400 l total volume) containing CMC or MC. Survival after 60 min 
perfusion with a final concentration of 1% CMC or MC was 90 and 100%, 
respectively (n=8), but mortality increased to 100% (n=3) when mice were perfused 
with 1.5% CMC, likely due to the viscous solution blocking the airways. For ethical 
reasons we did not expose mice to 1.5% MC because this solution was more viscous 
than 1.5% CMC. Subsequent nasal perfusion experiments were performed with a 
maximum of 1% MC and CMC final concentration.  
 
Dose-related increase in gene transfer   
The nasal epithelium of mice was initially perfused with GL67A/pCIKLux complexes 
(80 g in 400 l total volume) containing 0.5% and 1% CMC. Appropriate control 
groups receiving GL67A/pCIKLux without CMC (0%) and animals transfected with 
an irrelevant control plasmid, as well as untransfected mice, were also included 
(n=8/group). Nasal perfusion with 0.5% CMC containing GL67A/pCIKLux 
complexes significantly (p<0.05) increased gene expression approximately 3-fold 
compared to 0% CMC control group, whereas the addition of 1% CMC did not alter 
gene expression (Figure 1A). To confirm the results and to assess if lower 
concentrations of CMC might be beneficial, mice were perfused with 0.25% and 0.5% 
CMC containing GL67A/pCIKLux complexes (n=8/group). The significant increase 
with 0.5% CMC previously obtained was reproducible (p<0.05), but 0.25% CMC had 
no effect (Figure 1B). In contrast, 0.5% MC did not alter gene expression and 1%MC 
reduce gene expression (p<0.05, n=8/group) (Figure 1C). Thus, the effects of 
viscoelastic gels on non-viral gene transfer are formulation and concentration 
dependent, and subsequent nasal perfusion experiments were performed with a final 
concentration of 0.5% CMC. 
 
Prolonged contact time  
Our standard conditions for GL67A murine nasal perfusion studies include 80 g of 
plasmid DNA in a total volume of 100 l, perfused at a rate of approximately 7 
l/min over approximately 15 min [18]. We next assessed, if an extension of the 
perfusion time, and thereby prolongation of contact time between the gene transfer 
agent and the airway epithelium, could increase gene transfer efficiency. All mice 
were exposed to 80 g pCIKLux complexed to GL67 in either 150 or 400 l using a 
constant perfusion speed of 7l/min. The prolonged perfusion (60 min vs 22 min) of 
400 l lipid/DNA complexes increased gene transfer by 6-fold (n=8, p<0.05) (Figure 
2). Prolonging contact time further to a total of 5 hours, however, did not further 
improve gene transfer (60 min:  193.4±56.9, 300 min: 231.5±73.7 RLU/mg total 
protein, n=8). 
 
Prolonged contact time and viscoelastic gels  
We speculated that a combination of prolonged perfusion and the addition of 0.5% 
CMC may have an additive effect on non-viral gene transfer in the mouse nose.  
All mice were exposed to 80 g pCIKLux complexed to GL67 containing either 0% 
or 0.5% CMC in either 150 or 400 l using a constant perfusion speed of 
approximately 7 l/min. Importantly, a combination of prolonged perfusion and CMC 
further increased transfection efficiency to an overall 25-fold enhancement (n=8, 
p<0.001) in gene expression compared to our standard formulation (Figure 2).  
 
CMC for nebulisation  
We also assessed if CMC increased gene transfer in the mouse lung using whole body 
nebulisation chambers. 0.5% CMC was either nebulised for 1 hr immediately before, 
or simultaneously with, GL67A/pCIKLux. The former did not increase gene transfer 
(data not shown), whereas co-administration significantly increased gene transfer 
approximately 4-fold (p<0.0001, n=18) (Figure 3). Attempts to increase the 
concentration of CMC from 0.5% to 1% were unsuccessful as the high viscosity of the 
solution prevented nebulisation. 
 
Expression of vector-specific CFTR mRNA  
To date the levels of gene transfer achieved by non-viral vectors has been insufficient 
to detect recombinant CFTR protein or correction of the ion transport defect in the 
nasal epithelium of CF mice [18]. However, since a combination of prolonged contact 
time, and the addition of CMC, improved gene transfer in the mouse nasal epithelium 
by 25-fold compared to our previous formulation, we felt, that this increase in gene 
expression warranted a re-evaluation of whether these biomarkers could be altered by 
non-viral gene transfer.  
 
CF knockout mice were first transfected with pCIK-CFTR or pCIKGFP-CFTR 
complexed to GL67A containing 0.5% CMC, or remained untransfected (n=35/group) 
and mRNA was quantified 24 hr after transfection using quantitative RT-PCR. Gene 
expression was detectable in 69 out of 70 transfected mice. Median levels of gene 
expression were equivalent to 36% and 170% of endogenous CFTR in mice 
transfected with pCIK-CFTR and pCIKGFP-CFTR, respectively (Figure 4). mRNA 
levels were significantly (p<0.01) higher in pCIKGFP-CFTR transfected mice when 
compareed to pCIKCFTR . 
 
Expression of GFP-CFTR fusion protein  
CF-knockout mice were transfected with pCIKGFP-CFTR complexed to GL67A or a 
control plasmid without cDNA (pCIK-empty) (n=10/group). As a positive control for 
the immunohistochemistry (IHC), mice (n=6) were transfected with recombinant 
Sendai-virus (SeV) vector carrying the GFP-CFTR fusion contruct (SeV-GFP-CFTR, 
10
8
 pfu/mouse).  We have previously shown that this virus transduces the nasal 
epithelium  highly efficiently [16]. Despite extensive analysis of all tissues (300-400 
respiratory epithelial cells per level, ~1000 cells per mouse) we did not detect 
recombinant protein in pCIKGFP-CFTR transfected mice. In contrast, in mice 
transduced SeV-GFP-CFTR protein was detectable (Figure 5).  
 
 
 
Nasal potential difference measurements 
To ensure plasmids to be used in the study in vivo were able to generate functional 
CFTR channels, an in vitro radiotracer efflux assay was first performed. pCIKCFTR 
and pCIKGFP-CFTR both generated significant CFTR-mediated ion efflux, although 
the fusion cDNA lead to significantly (p<0.05) lower efflux activity compared to 
pCIKCFTR (Figure 6).  
 
Next, CF-knockout mice were transfected with pCIKCFTR, pCIKGFP-CFTR or pCI-
empty complexed to GL67A and 0.5% CMC as described above (n=30/group) and 
nasal Potential Difference (NPD) measurements were performed 24 hr after 
transfection. The baseline NPD and amiloride response are measures of sodium 
absorption, which are elevated in CF. The response to perfusion with a low chloride 
solution is a measure of CFTR-mediated chloride transport, which is absent or 
reduced in CF. There were no significant changes in baseline PD, amiloride response , 
or low chloride responses (Table 1) between mice treated with CFTR expressing 
plasmids and controls.  
 
 Discussion  
 
Here, we have shown that carboxymethylcellulose, a viscoelastic gel, significantly 
increases cationic lipid (GL67A)-mediated gene transfer to the airway epithelium. 
Gene transfer was further increased by prolonging contact time between the vector 
and the target cells; these two interventions were additive providing an approximately 
25-fold increase in reporter gene expression and up to 170% of endogenous CFTR 
mRNA levels in  knockout-mice. Interestingly, despite these changes neither CFTR 
protein nor changes in bioelectric properties could be detected.  
 
Sinn et al have previously shown that the viscoelastic gels MC and CMC significantly 
reduce mucociliary transport rates [4], which is likely to prolong contact time between 
the gene transfer agent and the lung epithelium and may explain the increased 
transfection efficiency of non-viral gene transfer agents observed in this study.  MC 
and CMC did not appear to open tight junctions in a polarised human airway 
epithelial cell model [4]. However, we observed, that the baseline nasal potential 
difference was reduced in the CF knockout mice treated with CMC (mean baseline 
PD approximately –15 mV) compared to our previously published CF mouse baseline 
values of approximately –24 mV [19]. This drop in baseline PD may be caused by the 
opening of tight junctions, or epithelial cell damage, which may also affect gene 
transfer efficiency. Interestingly, we have previously shown that tight junction 
openers increase non-viral gene transfer in murine airway epithelium [20]. It is, 
therefore, unclear if the effect of CMC is solely due to increasing contact time 
between vector and target cell.  
 
We observed a number of similarities and differences compared to the study by Sinn 
et al. which assessed the effect of CMC on virus-mediated transduction to airway 
epithelium [4]. (a) The maximum feasible concentration for nasal administration was 
similar.  At concentrations above 1% CMC and MC survival during nasal perfusion 
was low, likely due to mice being obligate nose breathers with the highly viscous 
solutions leading to blockage of the nasal passages. The maximum feasible 
concentration for nebulisation was determined by the ability to nebulise with the 
PARI LC+ nebuliser. It may be feasible to increase further the concentration by 
switching to other jet or ultrasonic nebulisers, or the most recently introduced mesh-
based nebulisers, (b) 1% CMC increased viral, but not non-viral gene transfer which 
may reflect the different properties or cellular uptake of viral and non-viral gene 
transfer agents, (c) MC improved viral, but not non-viral gene transfer. However, MC 
was less effective in reducing mucociliary clearance (MCC) than CMC [4], which 
may in part explain the results observed here.  
 
We also increased gene expression by prolonging perfusion of the lipid/DNA 
complexes onto the nasal epithelium. Lipid/DNA complexes enter cells through 
endocytosis and the amount of vector taken into the cell will, in part, depend on the 
endocytosis rate of the cells. It is, therefore, readily conceivable that prolonged 
contact time will allow more vector to be endocytosed, which in turn is likely to 
increase gene expression. Interestingly, we show here, that the effects of CMC and 
prolonged perfusion on gene transfer were additive. As mentioned above, it is unclear, 
if the cilia-static action of CMC is the main factor involved in increasing transfection 
or if CMC-induced opening of tight junctions also plays an important role. 
Independent of the mode of action, it is likely that prolonged contact time through 
longer perfusion would further enhance the effect.  
 
Using these optimised transfection conditions we next attempted to identify 
transfected cells using immunohistochemistry (IHC). In a previous study [18], we 
tried to quantify lipid-mediated CFTR expression by IHC in transfected CF knockout 
mice using a variety of anti-CFTR antibodies [18]. Interestingly, no CFTR expression 
could be detected even in control experiments following transduction with a Sendai 
virus (SeV) vector carrying a CFTR cDNA, which has been shown to transfect close 
to 100% of airway epithelial cells and partially corrects the chloride transport defect 
in the CF mouse nose [21,22]. Here we, therefore, used a GFP-CFTR fusion construct 
[10] and anti-GFP antibodies to visualise transfected cells. We first showed that GFP-
CFTR mRNA is detectable after GL67A/pCIKGFP-CFTR mediated gene transfer. 
Importantly, we used a novel cell harvesting technique that allowed detection of 
vector-specific mRNA in samples enriched to >80% for murine airway epithelial 
cells, rather than tissue homogenates. Interestingly, pCIKGFP-CFTR-derived mRNA 
levels were significantly higher than pCIKCFTR-derived levels. The reason for this is 
unknown, but an mRNA stabilising effect of the N-terminal GFP fusion may be 
responsible. However, although the anti-GFP antibody detected the GFP-CFTR fusion 
protein in SeV-GFP-CFTR transduced mice (positive control), we were unable to 
visualise protein expression in GL67A/pCIKGFP-CFTR transfected animals. After 
transduction the SeV vector replicates in the cytoplasm of transduced cells which 
likely leads to higher levels of recombinant protein expression per cell than 
GL67/pCIKGFP-CFTR expression, which may explain the results.  
 
We were also unable to detect changes in murine nasal bioelectrics. There may be 
several reasons for this: (1) Although significant levels of vector-specific mRNA are 
produced, these may only come from a very few highly expressing cells, rather than 
from many cells expressing CFTR at moderate to low levels. This would not be 
sufficient to correct the chloride transport defect, as in vitro mixing experiments imply 
that a minimum of 5% of cells expressing CFTR may be required [23]. Importantly, 
the quantitative RT-PCR assay does not currently provide information on how many 
cells express vector-specific CFTR mRNA, and further refinements of RT-PCR down 
to single-cell quantification are required. However, since SeV vector which transfects 
close to 100% of murine nasal epithelial cells, but only achieves modest correction 
(approximately 20% towards wild-type) [21], other factors may play a role. (2) 
Although the optimised transfection conditions used here led to 170% of vector-
specific mRNA compared to endogenous Cftr expression in the CF mice,  it is 
important to note that  murine Cftr expression is approximately 15-fold lower in the 
FABp-CF mice used here compared to wild-type mice[24], possibly due to increased 
mRNA degradation caused by knock-in of the stop codon and the neomycin resistance 
gene [25], or strain variation in Cftr expression. Thus, the maximum transgene levels 
achieved here, represent approximately 12% of endogenous wild-type Cftr levels, 
which may still be too low to correct mouse nasal PD. Importantly, however, CF 
subjects with “mild mutations” which maintain low levels of residual CFTR 
expression and function (≥ 5%) have generally less severe lung disease [26]. (3) 
Although, previous studies have shown that GFP fused to the N-terminus of CFTR 
neither affected chloride channel function nor the correct apical localization of CFTR 
[10,27], we observed a significant reduction in a radio-tracer efflux assay. Differences 
may be due to different models and assays being used in these studies. We cannot 
exclude that the fusion construct may have reduced chloride channel function in the 
mouse nose in vivo, although we have previously shown that when incorporated into 
SeV vector, partial correction of chloride transport can be achieved with this construct 
in CF mice [16]. Importantly, the non-modified CFTR cDNA also did not achieve 
correction.  (4) The suitability of the CF mouse nasal epithelium as a model for 
respiratory gene transfer has been put into question by two recent publications 
showing that the nasal bioelectrics are dominated by the olfactory rather than the 
respiratory epithelium [28,29]. Our experience is in keeping with this observation. 
Transduction with SeV vector, which targets both the respiratory and olfactory 
epithelium led to increases in chloride transport [21], whereas non-viral gene transfer 
agents such as GL67A and DC-Chol/DOPE, which have been optimised to transfect 
the airway epithelium, were unable to alter ion transport in the mouse nose. 
 
Prolonged contact time between the airway epithelium and gene transfer agents may 
also increase transfection efficiency in the human lung. Extending the nebulisation 
time may be one way to achieve this, although patient tolerability may become a rate 
limiting factor. As mentioned above CMC has been shown to be safe for use in man 
and may, therefore, be suitable for inclusion in gene therapy clinical trials. However, 
efficacy and tolerability have to be carefully assessed in a suitable pre-clinical model. 
We routinely use wild-type sheep because lung structure and cell composition are 
similar to human. The recently developed CF pig and ferret models [30,31] may allow 
assessment of these novel strategies in the context of CF lung disease. However, it 
remains to be seen, if CF pigs and ferrets develop CF-like lung disease and when 
these models will become available for the wider research community.  
 
Conclusions 
We have shown that prolonged contact time, achieved by either exposure to a 
viscoelastic gel or prolonged perfusion, or a combination of both, increases cationic 
lipid-mediated gene transfer to the mouse nasal epithelium. However, the achieved 
levels remain insufficient for detection of transfected cells with 
immunohistochemistry, or correction of ion transport defects in CF knockout mice.   
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Figure legends 
Figure 1: Addition of CMC increases gene transfer to mouse nasal epithelium 
Mouse nasal epithelium was perfused with pCIKlux (80 μg/mouse) or pCIKempty (negative control) 
complexed to GL67A or remained untransfected (UT) (perfusion rate: 7 μl/min). Viscoelastic gels to final 
concentrations ranging from 0.25% to 1% were added to the lipid/DNA complexes (final volume 150 
μl/mouse). 24 hr after transfection luciferase expression was quantified in tissue homogenate. (A and B) 
carboxymethylcellulose (CMC), (C) methylcellulose (MC). Bars represent group mean ±SEM 
(n=8/group). *=p<0.05 compared to 0% CMC.  
 
Figure 2: Prolonged perfusion increases gene expression in mouse nasal epithelium 
Mouse nasal epithelium was perfused with pCIKlux (80 μg/mouse) complexed to GL67A or remained 
untransfected (UT). Carboxymethylcellulose (CMC) to a final concentration of 0.5% was added to the 
lipid/DNA complexes. To increase contact time between epithelium and gene transfer agents the 
lipid/DNA complexes were either administered in 150 μl or 400 μl total volume and were then perfused 
onto the nasal epithelium (7 μl/min) for approximately 23 and  60 min, respectively. 24 hr after 
transfection luciferase expression was quantified in tissue homogenate. Bars represent group mean 
±SEM (n=8/group). ***=p<0.005 compared to 150 μl group.  
 
Figure 3: Addition of CMC increased gene transfer after nebulisation in mouse lung 
Mouse lungs were transfected with pCIKlux complexed to GL67A for one hour using a nebulisation 
chamber or remained untransfected (UT). Carboxymethylcellulose (CMC) to a final concentration of 
0.5% was added to the lipid/DNA complexes (25 mg DNA in 16 ml final volume). 24 hr after transfection 
luciferase expression was quantified in the lung homogenate. Bars represent group mean ±SEM 
(n=8/group). *=p<0.05 compared to 0% CMC 
 
Figure 4: Expression of vector-specific CFTR mRNA in mouse nasal epithelium 
The nasal epithelium of CF knockout mice was perfused with pCIKCFTR or pCIKGFPCFTR  (80 μg 
DNA/mouse) complexed to GL67A including 0.5% CMC (final volume 150 μl/mouse)  or remained 
untransfected (UT).  24 hr after transfection vector-specific and endogenous CFTR mRNA were 
quantified in nasal epithelium using real-time quantitative RT-PCR. Data are expressed as the ratio of 
vector-specific over endogenous CFTR mRNA. Each symbol represents one mouse (n=35/group). 
Horizontal bars indicates group median. In some samples mRNA was detectable, but not accurately 
quantifiable. These samples are labelled positive (pos). *=p<0.05 compared to pCIKCFTR, ***=p<0.001 
compared to untransfected. 
 
Figure 5: Detection of GFP-CFTR fusion protein in mouse nasal epithelium  
The nasal epithelium of CF knockout mice was perfused with pCIKGFPCFTR complexed to GL67A plus 
0.5% CMC. A recombinant Sendai virus (SeV) carrying GFP-CFTR was used as positive control and 
untransfected animals were negative controls.  24 hr after transfection nasal tissue was processed for 
immunohistochemistry and expression of GFP-CFTR fusion protein was visualized using an anti-GFP 
antibody and a secondary antibody conjugated to AlexaFluor 594. (A) SeVGFP-CFTR with anti-GFP 
primary antibody, (B) SeV-GFP-CFTR without anti-GFP primary antibody, (C) pCIKGFP-CFTR with anti-
GFP primary antibody, (D) untransfected mouse with anti-GFP primary antibody. GFP-CFTR protein 
appears in red. DAPI stained nuclei appear in blue. Representative images are shown. n=10 
mice/group. Scale bar=10 μm. 
 
Figure 6: Assessment of CFTR function in a radio-tracer efflux assay 
293T cells were transfected with either pCIKCFTR, pCIKGFP-CFTR or a negative control plasmid 
(pCIK-βgal) complexed to Lipofectamine 2000. 48 hr after transfection iodide efflux was quantified. Bars 
represent group mean ±SEM (n=6/group). *=p<0.05 
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Table 1:  
Nasal potential difference measurements in CF knockout mice transfected with  
CFTR-expression plasmids complexed to the cationic lipid GL67 
Numbers indicate group mean (SEM). For reference  non-CF low chloride 
responses are 9.5±3.5 mV.  
Plasmid 
Baseline 
(absolute PD) 
Amiloride 
(DPD ) 
 
Low Chloride 
(DPD) 
 
n 
pCIKCFTR 
-14.65     
(1.33) 
10.80        
(1.08) 
-0.48         
(0.38) 
31 
pCIKGFP-
CFTR 
-15.11     
(1.31) 
8.84          
(1.33) 
-0.49         
(0.37) 
30 
pCI-empty 
-15.99     
(1.41) 
11.61        
(1.35) 
-0.47         
(0.52) 
29 
